Related Experiment Video

Updated: May 27, 2025

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

2.5K

Cell cycle-based antibody selection for suppressing cancer cell growth

Chi Hun Song1, Chih-Wei Lin2, Kyung Ho Han1

  • 1Department of Biological Sciences and Biotechnology, Hannam University, Daejeon, Korea.

FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|February 15, 2025
PubMed

Insights

Researchers developed a new antibody screening method to inhibit cancer growth. The T1 antibody targets serine protease 3 (PRSS3), inducing cell cycle arrest and programmed cell death in tumor cells for potential cancer therapy.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Cell cycle arrest and programmed cell death are critical in cancer development.
  • Targeting cell fate decisions offers a therapeutic strategy for cancer.
  • Inducing cell cycle regulatory proteins in tumor cells is a key goal in cancer therapy.

Purpose of the Study:

  • To present a novel antibody selection method for inhibiting cancer growth.
  • To identify antibodies that induce cancer cells into G0/G1 phase, promoting cell cycle arrest and apoptosis.
  • To investigate the therapeutic potential of targeting serine protease 3 (PRSS3) in solid cancers.

Main Methods:

  • Antibody library screening using fluorescence-activated cell sorting (FACS) assays.
  • Cell cycle analysis to identify antibodies inducing G0/G1 phase arrest.
  • Mechanistic studies to elucidate the interaction between T1 antibody and PRSS3.

Main Results:

  • The T1 antibody was identified as effective in suppressing cancer cell proliferation.
  • PRSS3 was confirmed as the target antigen for the T1 antibody.
  • PRSS3 was shown to regulate tumor cell proliferation and apoptosis via interaction with the T1 antibody.

Conclusions:

  • PRSS3 is a promising therapeutic target for solid cancer treatment.
  • The developed antibody screening approach is effective and broadly applicable to various diseases.
  • Targeting PRSS3 with antibodies can induce cell cycle arrest and apoptosis, inhibiting cancer growth.
Keywords:
PRSS3antibodyantibody librarycancercell cycle

More Related Videos

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

3.5K
Analysis of Cell Cycle Position in Mammalian Cells12:19

Analysis of Cell Cycle Position in Mammalian Cells

Published on: January 21, 2012

60.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
105.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
463
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.0K